tiprankstipranks
Trending News
More News >
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
US Market

Eupraxia Pharmaceuticals (EPRX) Income Statement

Compare
21 Followers

Eupraxia Pharmaceuticals Income Statement

Last quarter (Q3 2025), Eupraxia Pharmaceuticals's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q3, Eupraxia Pharmaceuticals's net income was C$-8.85M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -235.25KC$ -209.91KC$ -193.27KC$ -111.53KC$ -116.81K
Operating Expenses
C$ 36.76MC$ 37.92MC$ 23.20MC$ 18.68MC$ 2.25M
Depreciation and Amortization
C$ 235.25KC$ 209.91KC$ 193.27KC$ 111.53KC$ 116.81K
EBITDA
C$ -33.72MC$ -37.40MC$ -22.14MC$ -21.96MC$ -2.01M
Operating Income
C$ -36.99MC$ -36.90MC$ -22.63MC$ -20.87MC$ -2.25M
Other Income/Expenses
C$ 1.73MC$ -2.29MC$ -64.07KC$ -5.46MC$ -1.76M
Pretax Income
C$ -35.27MC$ -39.18MC$ -23.92MC$ -23.37MC$ -4.01M
Net Income
C$ -34.94MC$ -37.39MC$ -23.26MC$ -22.99MC$ -4.00M
Per Share Metrics
Basic EPS
C$ -1.03C$ -1.58C$ -1.21C$ -1.61C$ -0.31
Diluted EPS
C$ -1.03C$ -1.58C$ -1.21C$ -1.61C$ -0.31
Weighted Average Shares Outstanding
33.93M 24.15M 19.29M 14.24M 12.87M
Weighted Average Shares Outstanding (Diluted)
33.93M 24.15M 19.29M 14.24M 12.87M
Currency in CAD

Eupraxia Pharmaceuticals Earnings and Revenue History